Multiple Myeloma

Autologous stem cell transplantation plus RVd improves PFS in multiple myeloma  

Presented By

Prof. Paul Richardson, Harvard Medical School, MA, USA

Trial

Phase 3, DETERMINATION

Conference

ASCO 2022

5 August, 2022 14:33

Promising results for novel CAR-T therapy in relapsed/refractory multiple myeloma

Presented By

Prof. Juan Du, Shanghai Chang Zheng Hospital, China

Conference

ASCO 2022

5 August, 2022 14:24

Post-transplant carfilzomib, lenalidomide, and dexamethasone outperforms post-transplant lenalidomide in multiple myeloma

Presented By

Dr Dominik Dytfeld, Poznan University of Medical Sciences, Poland

Trial

Phase 3, ATLAS

Conference

EHA 2022

1 July, 2022 11:24

Triplet therapy plus early ASCT improves PFS in newly diagnosed multiple myeloma versus triplet therapy alone

Presented By

Dr Paul Richardson, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, DETERMINATION

Conference

EHA 2022

1 July, 2022 11:21

Blood cancer patients show strong T-cell response to COVID vaccines

Conference

ASCO 2022

7 June, 2022 19:23

Teclistamab yields high response rate in relapsed multiple myeloma, carries high risk of side effects

Journal

 The New England Journal of Medicine

6 June, 2022 18:17

Cancer research advances presented at ASCO 2022 -part 1

6 June, 2022 15:32

GRIFFIN: Sustained responses of daratumumab plus RVd in MM

Presented By

Dr Jacob Laubach, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 2, GRIFFIN

Conference

ASH 2021

4 February, 2022 11:30

MajesTEC-1: Teclistamab efficacious in heavily pre-treated MM

Presented By

Prof. Philippe Moreau, University Hospital of Nantes, France

Trial

Phase 1/2, MajesTEC-1

Conference

ASH 2021

4 February, 2022 11:26

iStopMM: Smouldering MM highly prevalent in general population

Presented By

Dr Sigrún Thorsteinsdóttir, University of Iceland, Iceland

Trial

iStopMM

Conference

ASH 2021

4 February, 2022 11:25

Mechanisms of D-KRd treatment failure in MM identified

Presented By

Dr Eileen Boyle, NYU Langone Health, NY, USA

Conference

ASH 2021

4 February, 2022 11:22

TRIMM-2: Favourable results of talquetamab plus daratumumab for MM

Presented By

Dr Ajai Chari, Mount Sinai School of Medicine, NY, USA

Trial

Phase 1, TRIMM-2

Conference

ASH 2021

4 February, 2022 11:16

Support for fourth COVID-19 jab in blood-cancer patients

Journal

The Lancet

3 February, 2022 17:29

ASH 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ASH 2021

4 January, 2022 08:00

CAR-T cell therapy for multiple myeloma may lead to Parkinson’s-like symptoms

Journal

Nature Medicine

15 December, 2021 16:39

Vaccines weaker than expected in multiple myeloma patients

Journal

Cancer Cell

25 October, 2021 22:47

Some young people who undergo HCT retain ability to conceive

Journal

Human Reproduction

20 October, 2021 19:04

Limited evidence supports many hematopoietic stem cell transplant guidelines

Journal

JAMA Network Open

19 October, 2021 23:16

Triplet therapy for high-risk smoldering myeloma may delay progression to overt disease

Journal

JAMA Oncology

27 September, 2021 15:23

Immune therapy of multiple myeloma

Presented By

Prof. Noopur Raje, Massachusetts General Cancer Center, USA

Trial

KarMMA; CARTITUDE-1; UNIVERSAL

Conference

EHA 2021

5 August, 2021 14:49

MAIA results confirm superior efficacy of daratumumab with standard-of-care

Presented By

Prof. Thierry Facon, University of Lille, France

Trial

Phase 3, MAIA

Conference

EHA 2021

5 August, 2021 14:46

Different IV bisphosphonates dosing tied to similar skeletal event rates in multiple myeloma

Journal

JAMA Network Open

30 July, 2021 22:36

Multiple-myeloma patients may not mount adequate response to COVID vaccine

Journal

Cancer Cell

2 July, 2021 16:31

Adding daratumumab to triple therapy might help patients with newly diagnosed multiple myeloma

Journal

JAMA Oncology

21 April, 2021 15:56

Some older people with multiple myeloma can safely skip long-term steroids

Journal

Blood

8 April, 2021 17:35

CAR-T-cell multiple myeloma treatment effective in early trial

Journal

The New England Journal of Medicine

24 February, 2021 23:00

Validation of MY-RADS response assessment category criteria

Presented By

Dr Angelo Belotti, ASST Spedali Civili di Brescia, Italy

Conference

ASH 2020

18 February, 2021 10:43

High symptom burden in transplant-ineligible patients with newly diagnosed MM

Presented By

Dr Hira Mian, McMaster University, Canada

Conference

ASH 2020

18 February, 2021 10:42

Added value of ixazomib to lenalidomide plus dexamethasone in transplant-ineligible newly diagnosed MM

Presented By

Prof. Thierry Facon, University Hospital Lille, France

Trial

Phase 3, TOURMALINE-MM2

Conference

ASH 2020

18 February, 2021 10:37

Survival of transplant-eligible newly diagnosed MM in FORTE trial

Presented By

Dr Francesca Gay, GIMEMA, European Myeloma Network, Italy

Trial

Phase 2, FORTE

Conference

ASH 2020

18 February, 2021 10:35

Better survival with upfront autoSCT versus bortezomib-based intensification

Presented By

Prof. Michele Cavo, University of Bologna, Italy

Trial

Phase 3, EMN02/HO95

Conference

ASH 2020

18 February, 2021 10:29

Subcutaneous daratumumab plus pomalidomide and dexamethasone in R/R MM

Presented By

Prof. Meletios Dimopoulos, University of Athens, Greece

Trial

Phase 3, APOLLO

Conference

ASH 2020

18 February, 2021 10:26

Melflufen well tolerated with encouraging activity in heavily pretreated R/R MM

Presented By

Dr Enrique Ocio, University Hospital Marqués de Valdecilla, Spain

Trial

Phase 1/2, ANCHOR (OP-104)

Conference

ASH 2020

18 February, 2021 10:22

Initial data of FcRH5/CD3 T-cell-engaging bispecific antibody

Presented By

Dr Adam Cohen, University of Pennsylvania, Philadelphia, USA

Trial

Phase 1, GO39775

Conference

ASH 2020

18 February, 2021 10:20

Deep and durable responses with ide-cel in RRMM

Presented By

Dr Yi Lin, Mayo Clinic, Minnesota, USA

Trial

Phase 1, CRB-401

Conference

ASH 2020

18 February, 2021 10:17

Assessing measurable residual disease tied to better outcome in multiple myeloma

Conference

American Society of Hematology (ASH) Annual Meeting

21 December, 2020 20:46

Origins of blood cancer traced to early childhood, decades before diagnosis

Conference

American Society of Hematology 2020 Annual Meeting

17 December, 2020 17:42

Venetoclax boosts progression-free survival in myeloma patients, but may cause more deaths

Journal

Lancet Oncology

11 November, 2020 17:52

Isatuximab triplet improves PFS in R/R MM

Presented By

Prof. Philippe Moreau, University Hospital of Nantes, France

Trial

Phase 3, IKEMA

Conference

EHA 2020

9 September, 2020 10:26

Initial results from CAR-T cell therapy in MM: KarMMa

Presented By

Prof. Jesús San Miguel, University of Navarra, Spain

Conference

EHA 2020

9 September, 2020 10:19

Higher risk of severe COVID-19 seen in people with blood cancers

Journal

The Lancet Oncology

1 September, 2020 18:28

Carfilzomib: no PFS benefit for multiple myeloma

Presented By

Prof. Shaji K. Kumar, Mayo Clinica, MN, USA

Trial

Phase 3, ENDURANCE (E1A11)

Conference

ASCO 2020

28 August, 2020 16:00

Oral selinexor/pomalidomide/dexamethasone shows activity in heavily pre-treated multiple myeloma

Presented By

Dr Christine Chen, Princess Margaret Cancer Centre, University of Toronto, Canada

Trial

MM-003, STOMP

Conference

ASH 2019

5 March, 2020 22:59

BCMA-targeted CAR T therapy yields 100% response in relapsed/refractory MM

Presented By

Dr Deepu Madduri, Mount Sinai Medical Center, USA

Trial

Phase 1/2, CARTITUDE-1

Conference

ASH 2019

5 March, 2020 20:29

Adding daratumumab to carfilzomib/dexamethasone prolongs PFS and OS in R/R MM

Presented By

Prof. Saad Usmani, UNC-Chapel Hill School of Medicine, USA

Trial

Phase 3, CANDOR

Conference

ASH 2019

5 March, 2020 19:49

Anti-BCMA/anti-CD38 in refractory multiple myeloma

Presented By

Prof. Yu Hu, Huazhong University of Science and Technology, China

Conference

ASH 2019

5 March, 2020 16:31

ALCYONE: New overall survival results for myeloma

Presented By

Dr Maria Victoria Mateos, University Hospital of Salamanca, Spain

Trial

Phase 3, ALCYONE

Conference

ASH 2019

5 March, 2020 16:16

Off-the-shelf natural killer cells

Presented By

Dr Jode Goodridge, Fate Therapeutics, USA

Conference

ASH 2019

5 March, 2020 09:38

CASSIOPEIA trial: Phase 3 results of daratumumab + bortezomib/thalidomide/dexamethasone in multiple myeloma

Presented By

Prof. Phillippe Moreau, University Hospital of Nantes, France

Trial

Phase 3, CASSIOPEIA

Conference

EHA 2019

9 August, 2019 23:30

Chimeric antigen receptor T cell therapy in multiple myeloma

Presented By

Prof. Hermann Einsele, University of Würzburg, Germany

Conference

EHA 2019

9 August, 2019 22:34

Higher levels of treatment satisfaction without compromising efficacy: subcutaneous daratumumab in RRMM

Presented By

Prof. María-Victoria Mateos , University of Salamanca, Spain

Trial

Phase 3, COLUMBA

Conference

EHA 2019

9 August, 2019 21:36

Adding isatuximab to pomalidomide and dexamethasone improves PFS and ORR in RRMM

Presented By

Prof. Michel Attal, University Institute Cancer Toulouse Oncopole, France

Trial

Phase 3, ICARIA-MM

Conference

EHA 2019

9 August, 2019 20:38

Venetoclax for multiple myeloma: effective but some safety concerns

Presented By

Dr Shaji Kumar, Mayo Clinic, USA

Trial

Phase 3, BELLINI

Conference

EHA 2019

9 August, 2019 09:42

Daratumumab a promising treatment option for transplant-eligible multiple myeloma

Presented By

Dr Philippe Moreau, University Hospital Hôtel-Dieu, France

Trial

Phase 3, CASSIOPEIA

Conference

ASCO 2019

15 July, 2019 23:14

Anti-CD38 antibody isatuximab improves treatment response, PFS in R/R multiple myeloma

Presented By

Dr Paul G. Richardson, Dana-Farber Cancer Institute/Harvard Medical School, USA

Trial

Phase 2, ICARIA-MM

Conference

ASCO 2019

15 July, 2019 13:53